CING Cingulate Inc.
USHealthcareAs of 2026-07-02
Why CING matters now
Cingulate Inc. (CING) is a US stock in Healthcare. The latest InvestLog snapshot shows $5.38 with -8.66% on the session and $30.2M in market capitalization; recent performance reads 1-month +13.67% and YTD +14.98%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-9.3M, and EPS of $-1.71. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -70.7%.
The latest indexable market news headline is "Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $10.00; recent insider activity includes Hargroves Thomas Jeffrey filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.44
P/S
0.00
EV/EBITDA
-0.40
DCF Value
$0.05
FCF Yield
-70.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-365.2%
ROA
-89.8%
ROIC
-91.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-9.3M | $-1.71 |
| Q4 2025 | $0.00 | $-6.3M | $-0.87 |
| FY 2025 | $0.00 | $-22.4M | $-4.13 |
| Q3 2025 | $0.00 | $-7.3M | $-1.35 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$10.00
Target (Median)
$10.00
Target Range
$10.00 - $10.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.85
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.